LifeVantage (NASDAQ:LFVN) Shares Cross Above 200-Day Moving Average – Here’s What Happened

LifeVantage Co. (NASDAQ:LFVN) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $14.71 and traded as high as $17.63. LifeVantage shares last traded at $17.58, with a volume of 249,482 shares changing hands.

Analyst Ratings Changes

A number of research firms have commented on LFVN. Craig Hallum began coverage on shares of LifeVantage in a research report on Tuesday, January 14th. They issued a “buy” rating and a $35.00 target price for the company. Lake Street Capital began coverage on shares of LifeVantage in a research report on Thursday, December 19th. They issued a “buy” rating and a $26.00 target price for the company.

LifeVantage Stock Performance

The firm has a market cap of $220.65 million, a P/E ratio of 31.39 and a beta of 0.84. The business’s 50-day simple moving average is $20.07 and its 200 day simple moving average is $14.71.

LifeVantage (NASDAQ:LFVN) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.08. LifeVantage had a net margin of 3.46% and a return on equity of 34.29%.

LifeVantage Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Monday, March 3rd will be paid a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Monday, March 3rd. LifeVantage’s dividend payout ratio is presently 28.57%.

Insider Transactions at LifeVantage

In other news, Director Raymond B. Greer sold 8,000 shares of LifeVantage stock in a transaction on Monday, February 10th. The shares were sold at an average price of $20.15, for a total transaction of $161,200.00. Following the transaction, the director now owns 99,288 shares in the company, valued at $2,000,653.20. This trade represents a 7.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 20.65% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of LFVN. Capital Management Corp VA purchased a new position in shares of LifeVantage during the 3rd quarter valued at $5,073,000. HighTower Advisors LLC purchased a new position in shares of LifeVantage during the 3rd quarter valued at $638,000. Barclays PLC lifted its stake in shares of LifeVantage by 38.2% during the 3rd quarter. Barclays PLC now owns 41,966 shares of the company’s stock valued at $507,000 after buying an additional 11,608 shares in the last quarter. Ritholtz Wealth Management lifted its stake in shares of LifeVantage by 65.2% during the 4th quarter. Ritholtz Wealth Management now owns 47,348 shares of the company’s stock valued at $830,000 after buying an additional 18,682 shares in the last quarter. Finally, Copeland Capital Management LLC purchased a new position in shares of LifeVantage during the 4th quarter valued at $65,000. Hedge funds and other institutional investors own 35.32% of the company’s stock.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.